Skip to main content
. 2020 Oct 30;99(44):e22886. doi: 10.1097/MD.0000000000022886

Figure 2.

Figure 2

Mean concentration–time curves of serum trastuzumab emtansine (T-DM1), serum total trastuzumab, and plasma emtansine (DM1) in patients (n = 11) with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer after the first dose of T-DM1 at 3.6 mg/kg every 3 weeks. Error bars are standard deviation.